Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis [see comments]

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis [see comments]

Am J Respir Crit Care Med. 1996 May;153(5):1708-10. Unique Identifier : AIDSLINE MED/96210224
Asch S; Knowles L; Rai A; Jones BE; Pogoda J; Barnes PF; Department of Medicine, University of Southern California School; of Medicine, Los Angeles 90033, USA.

Abstract: To investigate the relationship between isoniazid resistance and HIV infection in patients with tuberculosis, we evaluated data in the Los Angeles County tuberculosis registry on 1,506 patients for whom drug susceptibility results were available. Among 235 HIV-infected patients, isoniazid resistance was less common than in 1,271 patients who were HIV-seronegative or who had not been tested for HIV, with an unadjusted odds ratio of 0.3. After adjustment for other factors that affect drug resistance (ethnicity, country of birth, prior diagnosis of tuberculosis, and cavitation), the frequency if isoniazid resistance remained lower than that in patients without HIV infection, with an odds ratio of 0.4 (95% confidence interval, 0.2 to 0.8; p = 0.02). We conclude that in Los Angeles, a setting where there is no ongoing outbreak of drug-resistant tuberculosis, isoniazid-resistant tuberculosis is not more common in HIV-infected patients.

Keywords: Antitubercular Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Confidence Intervals Drug Resistance, Microbial Ethnic Groups Female Human HIV Infections/*COMPLICATIONS HIV Seronegativity Isoniazid/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Likelihood Functions Linear Models Logistic Models Los Angeles Male Middle Age Mycobacterium tuberculosis/DRUG EFFECTS Odds Ratio Registries Retrospective Studies Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Tuberculosis, Multidrug-Resistant/*DRUG THERAPY Tuberculosis, Pulmonary/DIAGNOSIS/*DRUG THERAPY JOURNAL ARTICLE
Comment in: Am J Respir Crit Care Med 1996 May;153(5):1472-3
960930
M9690933

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .